Ra Capital Management, L.P. Dyne Therapeutics, Inc. Transaction History
Ra Capital Management, L.P.
- $4.58 Billion
- Q2 2025
A detailed history of Ra Capital Management, L.P. transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Ra Capital Management, L.P. holds 9,714,392 shares of DYN stock, worth $181 Million. This represents 2.02% of its overall portfolio holdings.
Number of Shares
9,714,392
Previous 9,714,392
-0.0%
Holding current value
$181 Million
Previous $102 Million
8.99%
% of portfolio
2.02%
Previous 2.11%
Shares
5 transactions
Others Institutions Holding DYN
# of Institutions
213Shares Held
125MCall Options Held
36.5KPut Options Held
74.3K-
Vanguard Group Inc Valley Forge, PA9.76MShares$182 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X09.44MShares$176 Million0.05% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$171 Million19.12% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$138 Million0.01% of portfolio
-
Fcpm Iii Services B.V. Naarden, P75.46MShares$102 Million14.09% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $967M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...